<Suppliers Price>

DRF-1042

Names

[ CAS No. ]:
200619-13-2

[ Name ]:
DRF-1042

[Synonym ]:
1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-12-(2-hydroxyethoxy)-, (4S,12S)-
(4S,12S)-4-Ethyl-4-hydroxy-12-(2-hydroxyethoxy)-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
5-(2'-Hydroxyethoxy)-20(S)-camptothecin
1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione,4-ethyl-4-hydroxy-12-(2-hydroxyethoxy)-,(4S)
UNII-461WVF206P

Biological Activity

[Description]:

DRF-1042 is an orally active camptothecin analog, which acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines[1][2].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> Cell Cycle/DNA Damage >> Topoisomerase

[References]

[1]. Chatterjee A, et al. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novelcamptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60.

[2]. Sriram Rajagopal, et al. Preclinical evaluation of the anticancer activity of DRF-1042, a novel camptothecin analog targeting Topoisomerase-I. Published April 2004.

Chemical & Physical Properties

[ Density]:
1.5±0.1 g/cm3

[ Boiling Point ]:
844.6±65.0 °C at 760 mmHg

[ Molecular Formula ]:
C22H20N2O6

[ Molecular Weight ]:
408.404

[ Flash Point ]:
464.6±34.3 °C

[ Exact Mass ]:
408.132141

[ PSA ]:
110.88000

[ LogP ]:
0.60

[ Vapour Pressure ]:
0.0±3.3 mmHg at 25°C

[ Index of Refraction ]:
1.726

Related Compounds